Clinical trials: Shingles
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.
- Trial name
- NCT01165229
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 213 sites in United States, Australia and 16 more
- Volunteers
- 14,819 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine
The purpose of this study is to evaluate consistency, immunogenicity and safety of live attenuated varicella vaccines manufactured at commercialized scale in aged 1-3 years children.
- Trial name
- NCT03555071
- Testing
- Vaccine manufactured at commercialized scale, Vaccine manufactured at trial-scale
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Prevention of Herpes Zoster (HZ)
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ vaccine.
- Trial name
- NCT04210752
- Testing
- Treatment 1 (EG-HZ-001), Treatment 2 (EG-HZ-002), Treatment 3 (EG-HZ-003)
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EyeGene Inc.
Varicella
Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)
This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.
- Trial name
- NCT00822237
- Testing
- Varicella Virus Vaccine Live (2007 Process) (Oka/Merck), Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck), Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses…
- Trial name
- NCT05015686
- Testing
- Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd, Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- Where
- China
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
- Trial name
- NCT00550745
- Testing
- Zoster Vaccine, Live
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chickenpox, Herpes Zoster
Immune Response to Varicella-Zoster Vaccination and Infection
Background: The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
- Trial name
- NCT00921999
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Background: Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18.
- Trial name
- NCT05580458
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay).
- Trial name
- NCT03120364
- Testing
- NBP608, Zostavax
- Where
- South Korea
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Herpes Zoster, Shingles
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
- Trial name
- NCT01600079
- Testing
- ZOSTAVAX™
- Volunteers
- 1,505,647 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Varicella
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.
- Trial name
- NCT03843632
- Testing
- VARIVAX™
- Where
- 5 sites in Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07354659
- Testing
- A zoster mRNA vaccine SYS6017, Active Comparator Vaccine
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Measles, Mumps
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
This study will compare the safety, tolerability, and immunogenicity of measles, mumps, rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with those of the 2006 process
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01536405
- Testing
- MMRV (AMP), MMRV (2006 process)
- Volunteers
- 1,412 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella Zoster, Immunization; Infection
Safety Study of NBP608 in Healthy Adult Volunteers
Indication: Protection against varicella and herpes zoster Study Objectives Primary: Safety and tolerability assessment after single dose administration of NBP608 Secondary: immunogenicity assessment after single dose…
- Trial name
- NCT03121638
- Testing
- VARIVAX, ZOSTAVAX, NBP6081
- Where
- South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Vaccine Reaction, Zoster
Reduced Vaccine Response to HZ/su in SLE
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without…
- Conditions
- Vaccine Reaction, Zoster, Systemic Lupus Erythematosus
- Trial name
- NCT07636044
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Measles, Mumps
Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines
The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00138255
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Varicella
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
This study assesses non-inferiority by comparing seroconversion rate of NBP608 to Varivax which are indicated for active immunization for prevention of varicella.
- Trial name
- NCT03114943
- Testing
- NBP608, Varivax
- Where
- Philippines
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Herpes Zoster, Herpes Zoster Vaccine
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine.
- Trial name
- NCT02075515
- Testing
- Herpes Zoster vaccine (GSK 1437173A)
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 651 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline